1 Comprehensive analysis across SMN2 excludes DNA methylation as an epigenetic 2 biomarker for spinal muscular atrophy

3

M.M. Zwartkruis^{1,2}, J.V. Kortooms¹, D. Gommers^{1,2}, M.G. Elferink², I. Signoria¹, J. van der 4 Sel^{1,2}, P.J. Hop^{1,4}, R.A.J. Zwamborn¹, R. Geene⁶, J.W. Green¹, H.W.M. van Deutekom², W. 5 6 van Rheenen¹, J.H. Veldink¹, F. Asselman¹, R.I. Wadman¹, W.L. van der Pol¹, G.W. van Haaften^{2*}, E.J.N. Groen^{1*} 7

8

9 ¹Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center 10 Utrecht, Utrecht, the Netherlands: ²Department of Genetics, University Medical Center Utrecht, Utrecht, 11 the Netherlands; ⁴Department of Translational Neuroscience, UMC Utrecht Brain Center; ⁵Center for 12 Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands; 6Utrecht Sequencing 13 Facility, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands; 14 ⁷Oncode Institute, Utrecht, the Netherlands. 15 16 *These authors contributed equally.

17

18 Correspondence: UMC Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands. g.vanhaaften@umcutrecht.nl, +31 8875 67747 (GWvH); e.j.n.groen-3@umcutrecht.nl, +31 19 20 8875 73834 (EJNG).

21

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 Abstract

23

24 Spinal muscular atrophy (SMA) is a severe neurodegenerative disease caused by defects in the survival motor neuron 1 (SMN1) gene. The wide variability in SMA severity is partially 25 26 explained by an inverse correlation with copy number variation of the second human SMN 27 gene (SMN2). Nevertheless, significant variability in severity and treatment response remains 28 unexplained, prompting a search for accessible biomarkers that could explain and predict this 29 variability. DNA methylation of SMN2 has been proposed as one such biomarker, but 30 comprehensive evidence and analyses are lacking. Here, we combined long-read nanopore 31 sequencing with targeted bisulfite sequencing to enable high-resolution analysis of SMN2-32 specific methylation patterns. We observed tissue-specific variation in DNA methylation across 33 the entire 30 kb SMN2 gene in 29 patients analyzed by long-read nanopore sequencing. 34 identifying variable methylation patterns in the promoter, introns, and 3' UTR. Subsequent 35 targeted analysis of these regions by bisulfite sequencing of blood-derived DNA in 365 SMA 36 patients showed no association between SMN2 methylation and disease severity or treatment 37 response, excluding blood methylation patterns as predictive biomarkers. However, we 38 discovered significant age-associated variation in SMN2 methylation, particularly in intron 1 39 and the 3' UTR, highlighting DNA methylation as a possible modifier of SMN expression during 40 development and aging. Our approach provides a broadly applicable strategy for detailed but 41 cost-effective and high-throughput characterization of DNA methylation in other genes and 42 diseases, including complex genetic regions.

43

Keywords: spinal muscular atrophy; survival motor neuron gene; DNA methylation; long-read
sequencing; bisulfite sequencing.

46 Introduction

47

48 Spinal muscular atrophy (SMA) is a devastating neurodegenerative disease characterized by progressive muscle weakness and atrophy that may cause infantile death or severe childhood 49 50 disability. The incidence is approximately 1 in 6,000-10,000 live births [1]. SMA is caused by 51 homozygous deletion or mutation of the survival motor neuron 1 (SMN1) gene, which results 52 in insufficient production of the critical and ubiquitously expressed SMN protein [2]. While SMA 53 patients lack a functional SMN1 gene, they retain one or more copies of the highly similar 54 SMN2 gene. The SMN2 gene can partially compensate for the loss of SMN1, but its ability to 55 do so is limited by alternative splicing that excludes exon 7, producing a truncated and 56 unstable form of the SMN protein [3–5]. The number of SMN2 gene copies, ranging from one 57 to six in patients with SMA, inversely correlates with disease severity, with higher copy 58 numbers associated with milder phenotypes [6,7]. However, this relationship is not absolute, 59 and significant variability in clinical presentation exists even among patients with the same 60 SMN2 copy number [6,8]. Additionally, the expression of SMN is strongly developmentally 61 regulated through unknown mechanisms, with high pre- and neonatal expression followed by 62 a reduction later in life [9,10]. Finally, treatment response to the three currently available gene-63 targeted therapies varies between patients with equal SMN2 copy numbers [11,12]. These 64 observations suggest that factors beyond SMN2 copy number may influence SMN protein 65 expression and SMA outcomes.

66 One potential source of this variability may lie in the epigenetic regulation of SMN2, as has often been hypothesized [7,11,13–16]. DNA methylation is a key epigenetic mechanism 67 68 that can influence gene expression without altering the underlying DNA sequence [17]. 69 Previous studies have identified differential methylation patterns in the SMN2 promoter region 70 between SMA patients with varying disease severities, suggesting that DNA methylation may 71 influence SMN2 expression [18,19]. Furthermore, the methyl-CpG-binding protein MECP2 has 72 been shown to interact with methylated sites in the SMN2 promoter, potentially regulating SMN 73 gene activity [18,20]. Several studies investigated genome-wide differential DNA methylation

74 in SMA patients, however with limited sample sizes [21,22]. While these initial findings are 75 intriguing, the existing literature on SMN2 methylation in SMA is limited, often focusing on a 76 small number of CpG sites within the promoter region and in small patient cohorts. Our overall understanding of variation in DNA methylation in patients with SMA therefore remains limited. 77 78 To fully elucidate the role of DNA methylation in the regulation of SMN2, a more 79 comprehensive analysis across the entire gene is warranted. In this study, we therefore aimed 80 to provide a detailed characterization of DNA methylation patterns across SMN2 in a large 81 cohort of patients with SMA, using a combination of long-read nanopore sequencing and 82 targeted bisulfite sequencing. We identified lowly methylated CpG sites in the SMN2 promoter. 83 the transcription site of the long non-coding RNA SMN-AS1, several intronic regions, and the 84 3' UTR of SMN2, with tissue-specific differences. No association between DNA methylation 85 and disease severity or treatment response was found, ruling out DNA methylation as an 86 epigenetic biomarker of SMA. DNA methylation was significantly associated with age at the 87 SMN2 3'UTR and intron 1, suggesting these changes might be involved in the regulation of 88 SMN expression during development and aging.

90 Results

91

92 Nanopore sequencing reveals extensive variation in DNA methylation across SMN2 and

93 copy-specific differential methylation between SMN2 haplotypes

94 To comprehensively explore DNA methylation across SMN2 in SMA patients, we determined 95 CpG methylation status from nanopore sequencing data from 10 blood samples and 22 96 fibroblast samples from 29 patients with varying SMN2 copy numbers and SMA types (Table 97 **S1**) [23]. We aligned the sequencing reads to *SMN1* by masking *SMN2* and phased the reads 98 into two to five haplotypes as described previously [23]. We analyzed DNA methylation per 99 patient and per SMN2 haplotype (Fig. 1A) and visualized the methylation percentage per CpG 100 site in a heatmap (Fig. 1B). In addition to low methylation of the promoter region, low 101 methylation was also observed in the transcription site of the IncRNA SMN-AS1 [14]. the 3' 102 UTR and various other, intronic regions of SMN2. Hierarchical clustering (Fig. 1B) and 103 principal component analysis (PCA, Fig. 1C) showed that methylation data from fibroblast and 104 blood clustered separately, as expected based on previous reports showing variation in DNA 105 methylation between tissues [24]. Fifty-eight sites were differentially methylated (p_{adi}<0.01) 106 between blood and fibroblasts (Fig. 1B and 1D). Because of this, subsequent analyses were 107 performed separately for each tissue. When exploring a possible correlation between DNA 108 methylation and disease severity by SMA type in this small group of samples, no differentially 109 methylated sites were found (Fig. 1E-F). We and others previously identified multiple single 110 nucleotide variants (SNVs) that can be used to study the genomic environment of individual 111 SMN copies and serve as markers of gene conversion [23,25] and used these insights to next 112 study DNA methylation per SMN haplotype (Fig. S1A). When comparing SMN2 haplotypes 113 with SMN1 environment SNVs to those with SMN2 environment SNVs (Fig. 1G), we found 114 five differentially methylated CpG sites in blood and seven in fibroblasts (p_{adi}<0.01), of which 115 four overlapped (Fig. 1H-I, Fig. S1). However, most of these are at known SNV positions [23] 116 (Fig. S1B-C), and these differences are therefore likely caused by a nucleotide variant in the 117 CpG site, resulting in a non-CpG site (Fig. 1J). Non-CpG methylation is possible in humans,

but its properties and functions are not well known [26,27]. Hence, it was not included in the methylation calling algorithms of this study (**Methods**). Interestingly, although based on a limited number of observations, one of the differentially methylated sites in blood (chr5:71381516, promoter region) was not a known SNV site, indicating a possible association between gene environment and methylation status. In summary, ONT sequencing allowed us to study DNA methylation across the entire *SMN2* gene and led us to identify several regions of interest (ROIs) for further analysis in a larger cohort.

125

126 DNA methylation in the SMN2 gene can be determined by targeted bisulfite sequencing

127 To investigate whether variation in DNA methylation identified by ONT sequencing was linked 128 to disease severity or treatment response, we performed targeted bisulfite sequencing on DNA 129 isolated from blood from 365 SMA patients (Fig. S2, Table 1, Table S2-3). Per patient, we 130 pooled 18 amplicons containing the ROIs identified by ONT sequencing (Fig 2A, Table S4), 131 15 of which were successfully sequenced by barcoded Illumina sequencing (>100x read depth 132 in at least 90% of patients). We included only CpG sites that were mapped on the intended 133 targets with at least 100x read depth and excluded potential SNV sites (Fig. S3A). Median 134 read depth per CpG site was 3,014-37,870x and for every CpG site, 95-100% of the patients 135 had a methylation call (Fig. S4A-B). For nine patients, both nanopore and bisulfite methylation 136 data was available; methylation percentages showed high correlation between data types 137 (Spearman's R=0.77, p<2.2e-16, Fig. S4C). Heatmap visualization of methylation percentage 138 per CpG site illustrated that most variation was present in the promoter region and 3'UTR. We 139 performed hierarchical clustering of patients and found that clustering was mostly based on variation in intron 1 and the 3' UTR of SMN2 (Fig. 2B). We performed further dimensionality 140 reduction of the dataset by filtering out CpG sites with little variation in methylation percentage 141 (standard deviation <5%) and CpG sites with high correlation (Spearman R>0.9), resulting in 142 143 57 sites for further analysis and statistical testing (Fig. S3A-B).

144

145 DNA methylation significantly correlates with age at 22 CpG sites across SMN2

146 To explore whether DNA methylation was associated with baseline patient characteristics -147 such as sex and age – we performed PCA, excluding patients with uncommon genotypes: 148 carriers of an SMN1 copy with loss-of-function variants or the positive modifier c.859G>C in 149 SMN2. Male and female groups completely overlapped (**Fig. 3A**), whereas age group clusters 150 only partly overlapped (Fig. 3B). Differential methylation analysis did not yield differentially 151 methylated sites between male and female patients (Fig. 3C). In contrast, DNA methylation 152 was significantly associated with age at 15 sites including three collapsed sites (p_{adi}<0.01, Fig. 153 **3D**), corresponding to 22 CpG sites in total. Interestingly, DNA methylation percentage 154 increased with age at one site (promoter region) but decreased at all other significantly 155 associated sites in intron 1, the 3' UTR and the IncRNA SMN-AS1 sequence (Fig. 3E). As this 156 association implies that age may be a confounding variable, we corrected for it in our 157 subsequent statistical analyses. The sites associated with age did not contain common 158 nucleotide motifs (Fig.S5). Altered DNA methylation may affect binding of CCCTC-binding 159 factor (CTCF), which may in turn affect 3D genome organization and alternative splicing [28-160 30]. However, CTCF binding site motifs (CTCF HUMAN.H11MO.0.A on 161 hocomoco11.autosome.org [31]) did not overlap with any of the age-related CpG sites in 162 SMN2 [32] (Fig. S6). To investigate whether age-associated changes in SMN2 DNA 163 methylation affect SMN2 mRNA expression, we made use of previously generated expression 164 data from whole blood [8]. We found that SMN2-FL RNA expression was significantly 165 associated with age in patients with three copies of SMN2, but not in patients with four copies 166 of SMN2 (Fig. S7A), possibly because this group did not include patients younger than 6 years 167 old and the sharpest decline of SMN expression happens perinatally [9]. We tested whether 168 there was an association between DNA methylation and SMN2-FL expression in patients with 169 three SMN2 copies. An association can be observed between DNA methylation and SMN2-FL expression at most CpG sites associated with age, where methylation appeared to be 170 171 higher in patients with higher SMN2-FL expression (Fig. S7B), although these associations 172 were not statistically significant (Fig. S7C).

173

174 No association between DNA methylation in SMN2 and disease severity or treatment

175 response

176 To investigate whether DNA methylation was associated with disease severity or treatment 177 response, we first analyzed patients with genetic variants that potentially modify disease 178 severity separately. We found no association between DNA methylation and presence of 179 SMN1 or the c.859G>C variant in SMN2 (Fig. S8). Patients with these genotypes were 180 excluded from further analyses, since their phenotypes are likely affected by these genetic 181 variants. To test if DNA methylation was associated with SMN2 copy number, we first 182 performed PCA that suggested there might be differences between copy number groups (Fig. 183 **4A**). However, this observation was likely confounded by age as mentioned above, since 184 patients with lower SMN2 copy number are often sampled at younger ages than patients with 185 higher copy number. Indeed, when correcting for age, none of the tested sites were 186 significantly associated with SMN2 copy number (Fig. 4C). Similarly, no association was found 187 between DNA methylation and copy number of the NAIP gene (Fig. S9A), which has also 188 been suggested as a potential modifier of SMA, although inconclusively [13]. No significantly 189 differentially methylated sites were found for disease severity by SMA type (Fig. 4B and 4D) 190 or age at onset (Fig. S9B). No differentially methylated sites were found when comparing SMA 191 types or ages at onset in patients with three or four SMN2 copies separately (Fig. S9C-F). In 192 addition, we tested the differentially methylated CpG sites from previous work [19] specifically, 193 but did not replicate any of these associations in our cohort (Fig. S10). Finally, we compared 194 changes in the commonly used Hammersmith functional motor scale (HFMSE) scores of a 195 cohort of patients with three or four SMN2 copies before and 1.5 years after nusinersen 196 treatment initiation (dHFMSE, n=111 Fig. 4E). Based on dHFMSE, patients were divided in 197 three treatment response groups: decline, stabilization, and increase. PCA did not show clear 198 clustering of these groups (Fig. 4F), and no CpG sites were significantly associated with 199 dHFMSE (Fig. 4G). These observations do not completely exclude the possibility that in 200 individual or rare changes in DNA methylation may still affect SMA outcomes. However, the 201 absence of associations between variation in SMN2 DNA methylation and disease severity or

treatment response in these analyses excludes SMN2 DNA methylation as an epigenetic

203 biomarker of SMA in blood.

205 Discussion

206

207 An important outstanding question in the SMA field is the absence of a clear correlation 208 between phenotype and genotype, even among patients with equal SMN2 copy number. 209 Variation in DNA methylation of SMN2 has long been hypothesized as a possible explanation 210 for this discrepancy [7,11,13–16]. Indeed, several previous studies suggested that variation in 211 DNA methylation could be a potential modifier of SMA [18,19], but these studies were limited 212 by technological possibilities and sample size, and comprehensive analyses of DNA 213 methylation across the complete SMN2 gene in large SMA patient cohorts had not been done 214 previously. In this study, we addressed this issue by combining long-read nanopore 215 sequencing to first discover variability in DNA methylation across the complete SMN2 gene in 216 a limited group of patients, followed by targeted bisulfite sequencing across the identified sites 217 in a large cohort of 365 SMA patients. We identified variable DNA methylation at multiple sites, 218 including the SMN2 3'UTR and the intronic transcription site of IncRNA SMN-AS1. DNA 219 methylation was significantly associated with age at all tested sites in intron 1 and the 3' UTR 220 of SMN2, and two CpG sites in the promoter and three CpG sites in the transcription site of 221 IncRNA SMN-AS1. However, DNA methylation was not significantly associated with SMN2 222 copy number, disease severity, treatment response, or SMN2-FL mRNA expression. In 223 summary, our results exclude variation in DNA methylation in SMN2 as an epigenetic 224 biomarker of clinical SMA outcomes but highlight DNA methylation as a possible modifier of 225 SMN expression.

226

We did not identify methylation differences in the *SMN2* promoter between SMA types in patients with three copies of *SMN2* as reported previously [19]. This previously reported difference may have been observed due to a lower sample size (n=35 versus n=211 in our study) or lenient multiple testing correction due to inclusion of a much smaller number of CpG sites. Another previous study specifically investigated DNA methylation in a group of patients with two *SMN2* copies and either SMA type 1 or SMA type 3. We were unable to replicate

233 these results as the number of patients with two SMN2 copies in our cohort was limited. In 234 addition, the combination of two SMN2 copies and SMA type 3 is extremely uncommon, and 235 it cannot be ruled out that the patients included in the previous study were carriers of rare 236 positive modifiers such as c.859G>C or c.835-44A>G, which were not commonly 237 characterized at the time that study was performed. We did not find association between DNA 238 methylation and disease severity in blood as accessible biomarker tissue, but DNA methylation 239 may still play a role in disease-relevant inaccessible tissues such as the spinal cord. Although 240 we did not find DNA methylation in blood measured before treatment initiation to be associated 241 with treatment response in this study, there is still the possibility that epigenetic marks might 242 be involved in the regulation of exon 7 inclusion during treatment [33]. Therefore, longitudinal 243 epigenetic studies may still hold promise for identifying additional targets to strengthen the 244 ability of splice modifiers to increase SMN expression.

245

246 In contrast to limited variability in DNA methylation in the SMN2 promoter region, we observed 247 significant variation in the SMN2 3'UTR. Previous studies have associated 3'UTR methylation 248 of other genes with both increased gene expression [34-36], decreased gene expression [37-249 42], or both [43,44]. Therefore, it is likely that 3'UTR DNA methylation can affect gene 250 expression in different ways for different genes, and through different mechanisms, such as 251 altered protein binding [45], alternative polyadenylation [46,47] or alternative splicing [41]. In 252 the SMN genes specifically, Marasco et al. showed that a nusinersen-like ASO promotes 253 chromatin-silencing mark H3K9me2, slowing down RNA polymerase II elongation and 254 inhibiting exon 7 inclusion [33]. Reduced DNA methylation in gene bodies is linked to 255 increased chromatin accessibility [48], and increased DNA methylation and H3K9 methylation 256 with heterochromatin [49]. Therefore, reduced DNA methylation at the 3' end SMN2 could 257 potentially be associated with faster RNA polymerase II elongation and increased exon 7 258 inclusion. Although we identified no significant association between SMN2-FL expression and 259 DNA methylation in blood, further association analyses between DNA methylation and (long-

read) RNA sequencing in other tissues may indicate whether DNA methylation affects splicing
and expression of specific exons and isoforms of the *SMN* gene.

262

263 DNA methylation is associated with age across mammalian tissues, and this association can 264 be either positive or negative, varying per CpG site [50]. Our current study identified several CpG sites, mostly located in intron 1 and the 3' UTR of SMN2, that were associated with age 265 266 in our patient cohort. For most sites, we observed that higher age was associated with reduced 267 levels of DNA methylation. A similar pattern was found in the TARDBP gene in human motor cortex of healthy subjects and ALS patients, and accelerated DNA demethylation in ALS was 268 269 associated with earlier disease onset [41]. Therefore, it would be interesting to determine 270 whether age-related decrease of DNA methylation in SMN2 is also present in healthy subjects. 271 Analyzing this in large control cohorts, however, is challenging as short-read sequencing of 272 bisulfite converted DNA samples does not allow to distinguish SMN1 and SMN2 in persons 273 that carry both genes in contrast to SMA patients who only carry copies of SMN2. This may 274 become possible in the future when long-read sequencing allowing haplotype-based analysis 275 becomes more routine and scalable. Previous research has shown that SMN protein levels 276 decline rapidly during the perinatal period in *post-mortem* spinal cord [9]. Similarly, SMN 277 mRNA and SMN protein expression have been reported to decrease with age in peripheral 278 blood mononuclear cells [10] but remain relatively stable in primary fibroblasts derived from 279 adult patients [10,51]. These findings highlight the potential differences in SMN requirements 280 between young children and adult patients, with potential implications for treatment 281 requirements. While infants and young children may benefit from therapies that maximize 282 SMN expression especially during the first few months of life, this may change in adulthood 283 when patients may have different needs in terms of maintaining sufficient SMN levels as they age. The age-related changes in SMN2 methylation patterns observed in our study could 284 285 represent an important consideration for the development of epigenetic therapies that aim to 286 modulate SMN expression across the lifespan. Although speculative, strategies based on the 287 use of catalytically inactive Cas9 (dCas9) fused to the catalytic domain of TET1 (TET1CD) for

- 288 demethylation [52] or the catalytic domain of DNA methyltransferase 3A (DNMT3A) to increase
- 289 methylation [53], could form a potential epigenetic therapeutic target for SMA.
- 290

291 Conclusions

292

- 293 We used nanopore long-read sequencing to reveal extensive variation in DNA methylation
- across the SMN2 gene, with low methylation levels observed not only in the promoter region
- but also in the transcription site of *SMN-AS1*, the 3' UTR, and various intronic regions. With
- 296 targeted bisulfite sequencing of 365 SMA patients, no associations were found between DNA
- 297 methylation and sex, *SMN2* copy number, disease severity or treatment response, excluding
- 298 DNA methylation in SMN2 as an epigenetic biomarker of clinical SMA outcomes. We
- 299 identified 22 CpG sites across SMN2 where DNA methylation was significantly associated
- 300 with age, highlighting DNA methylation as a possible modifier of SMN expression during
- 301 development and aging.

303 Methods

304

305 Study population

306 We included 370 SMA patients from our single-center prevalence cohort study in the 307 Netherlands, as detailed in Table 1 and Table S1-3; 24 patients overlap between nanopore 308 and bisulfite sequencing datasets. The study protocol (09307/NL29692.041.09) was approved 309 by the Medical Ethical Committee of the University Medical Center Utrecht and was registered 310 in the Dutch registry for clinical studies and trials (https://www.ccmo.nl/). Written informed 311 consent was obtained from all adult participants, as well as from parents or guardians for 312 patients under 18 years of age. SMN1, SMN2, and NAIP copy numbers were quantified using 313 multiplex ligation-dependent probe amplification (MLPA) (MRC Holland, SALSA MLPA 314 Probemix P021 SMA Version B1) followina the manufacturer's instructions 315 (https://www.mrcholland.com/). The clinical classification of SMA type was conducted based 316 on motor milestones and age at onset as previously described, with type 1 as non-sitters, type 317 2 as sitters, and type 3 and 4 as walkers [54]. To capture the broad genotypic and phenotypic 318 diversity within the SMA population, the study included patients with SMN2 copy numbers 319 ranging from two to five, and SMA types ranging from 1b to 4. Whole blood samples were 320 collected in EDTA tubes for DNA extraction, and 3 mm dermal biopsies were obtained for the 321 generation of primary fibroblasts. For 111 patients with three or four SMN2 copies and 322 receiving nusinersen treatment, Hammersmith Functional Motor Scale – Expanded (HFMSE) 323 scores were available that had been determined before treatment start and 1.5 years after 324 treatment initiation. For PCA, we stratified patients based on treatment response: decrease 325 for dHFMSE≤-3; stabilization for -3<dHFMSE<3; increase for dHFMSE≥3 [55].

326

327 DNA extraction and bisulfite conversion

328 For bisulfite sequencing, DNA was extracted from whole EDTA blood with the BI chemagic

329 DNA Blood 4k kit (Revvity, CMG-1074). DNA concentration was quantified with the Quant-

330 iT[™] 1X dsDNA BR Assay (Invitrogen, Q33267). Genomic Quality Number (GQN) was

determined with the Fragment Analyzer Genomic DNA 50kb Kit (Agilent, DNF-467). 500ng of
DNA was bisulfite-converted using the EZ-96 DNA Methylation-Lightning Kit (Zymo, D5033)
according to the manufacturer's instructions. Concentration of converted DNA was
measured with a spectrophotometer (Thermo Scientific, Nanodrop 2000) with the ssDNA
setting.

336

337 Polymerase chain reaction for bisulfite amplicon sequencing

338 Primers to amplify the top strand of bisulfite-converted DNA were designed with the Zymo 339 Bisulfite Primer Seeker (https://zymoresearch.eu/pages/bisulfite-primer-seeker) with default 340 options and intended product sizes of 450-550bp. Primers included a sequencing adapter-341 compatible overhang (5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3' to 5' end of 342 the forward primer, 5'-GTCTCGTGGGGCTCGGAGATGTGTATAAGAGACAG-3' to 5' end of 343 the reverse primer). Primer sequences (Integrated DNA Technologies) and amplicon-specific 344 conditions are listed in Table S4. Eighteen PCRs were performed on each bisulfite-345 converted patient DNA sample. Each 10uL PCR reaction contained 2.4uL PCR-grade water, 346 5µL KAPA HiFi HotStart Uracil+ ReadyMix (2X) (Roche, 7959052001), 0.3µL of each primer 347 (10µM), and a variable amount of DNA optimized for each reaction (Table S4). The PCR 348 was run using a Biorad T100 thermocycler (#1861096) with the following protocol: 95°C for 3 349 minutes; 36 cycles of 98°C for 30 seconds, annealing at variable temperatures for 15 350 seconds (ramp rate 0.5°C/s), followed by 72°C for 15 seconds (ramp rate 1.1°C/s); and a 351 final elongation at 72°C for 1 minute. All 18 amplicons were visualized on a 2% agarose gel containing Sybr Safe (Fisher Scientific, #10328162) for a subset of eight randomly selected 352 353 samples and imaged on a Biorad ChemiDoc[™] MP Imaging System (#12003154). Band 354 intensity was quantified with Fiji software (version 1.54). Relative band intensity was used for 355 determining the pooling ratio for amplicon pooling, e.g. a relative brightness of 2x resulted in 356 a pooling ratio of 0.5x. All 18 amplicons were pooled per patient and subsequently cleaned 357 with AMPure XP beads at a ratio of 0.65x to eliminate PCR reagents and small DNA 358 fragments. A subset of samples was run on the Agilent 2200 TapeStation (#G2965A) with

Agilent High Sensitivity D1000 ScreenTape (5067-5584) and High Sensitivity D1000

360 Reagents (5067-5585) to check for overamplification.

361

362 Library preparation and Illumina sequencing

363 A second PCR was performed on each patient sample containing 18 pooled amplicons to 364 attach Illumina DNA/RNA UD Indexes Sets A-D (Illumina, 20091654, 20091656, 20091658, 365 20091660) barcodes to the compatible overhangs that were included in the first PCR (see 366 above). Each 25uL PCR reaction contained 5.5µL PCR-grade water, 12.5µL NEBNext Q5 367 Hot Start HiFi PCR Master Mix (NEB, M0544L), 2.5µL of unique Illumina® DNA/RNA UD 368 Index, and 2.5ng of DNA in a volume of 2µL. The PCR was run in a Biorad T100 369 thermocycler with the following steps: 98°C for 30 seconds; six cycles of 98°C for 10 370 seconds followed by 65°C for 75 seconds: and a final elongation at 65°C for five minutes. 371 The PCR products were purified with AMPure XP beads at a ratio of 0.8x. A subset of 372 samples was measured on the Agilent 2200 TapeStation with Agilent High Sensitivity D1000 373 ScreenTape and High Sensitivity D1000 Reagents to check if the Illumina DNA/RNA UD 374 Indexes had successfully annealed. The concentration of a subset of individual samples was 375 measured with the Qubit dsDNA High Sensitivity kit (Thermo Fisher Scientific, #Q32854) kit 376 to check if concentrations were roughly equal, and all samples were pooled at equal volume. 377 The DNA concentration of the final pooled library was measured with the Qubit dsDNA High 378 Sensitivity kit. 785pM library with 2% PhiX Sequencing Control was loaded onto an Illumina 379 Nextseq2000 P1 flow cell and sequenced with 2x300bp paired-end read settings.

380

381 Nanopore data processing

Nanopore sequencing data was generated previously (Table S1)[23]; one patient was
excluded due to a partial deletion of *SMN1* exon 1-6, another patient was excluded due to
unavailability of clinical data. In summary, raw sequencing data was basecalled with Guppy
v6.1.2 with the SUP model (dna_r9.4.1_450bps_modbases_5mc_cg_sup.cfg) and mapped
to the T2T-CHM13 reference genome masked for a ~170kb region surrounding *SMN2* [23]. If

data from both blood and fibroblasts of the same patient was available, this data was not
merged. Polyploid haplotype phasing was performed with GATK and WhatsHap as
described previously [23]. Methylation calling was performed for full bam files and perhaplotype bam files with modbam2bed v1.0 with options -e -m 5mC -r chr5:7137500071425000 --cpg. Methylation calls from forward and reverse strands were merged per CpG
site. Methylation percentage was calculated from modbam2bed output with the formula:
Nmod / (Nmod + Ncan) * 100.

394

395 Illumina data processing

396 Bisulfite sequencing data was processed with the methylseg v2.6.0 workflow from nf-core 397 [56], including raw data QC with FastQC, adapter sequence and guality trimming (Phred<20) 398 with Trim Galore!, read alignment to the masked T2T-CHM13 reference genome [23] with 399 Bismark and extraction of methylation calls with Bismark. Default options were used, except 400 for: --unmapped, --skip deduplication and --save align intermeds. For each sample, the 401 bismark.cov.gz file from the methylation coverage output directory was loaded into R4.4.0 402 [57] and the data for all samples were merged into one dataset. Methylation percentage was 403 used directly from the cov.gz file. The data was filtered to only contain CpG sites that are 404 located on the intended amplicons and had a read depth (methylated reads + unmethylated 405 reads) of 100x or more. When the C or G of a CpG site was a known SNV position [25], it 406 was removed, to prevent any SNVs to be mistakenly interpreted as methylation changes, 407 since unconverted DNA was not sequenced. Additional data filtering was applied before 408 statistical testing with linear models, to reduce dimensionality: sites with little variation 409 between samples (methylation percentage standard deviation <5%) were removed, and 410 highly correlated sites with Spearman's R>0.9 were treated as one site by averaging (Fig. 411 S3).

412

413 Visualization and exploration of methylation data

414	Methylation percentages were visualized per sample or per haplotype using the pheatmap
415	v1.0.12 package [58] in R v4.4.0. Row clustering was performed with the ward.D2 method
416	and Euclidian distance. PCA was performed with the function PCA from the FactoMineR
417	v2.11 package [59] followed by the function fviz_pca_ind from package factoextra v1.0.7

418 [60].

419

420 DNA motif analyses

421 The sequence surrounding the tested CpG sites (20bp upstream and 20bp downstream)

422 was extracted with bedtools v2.30.0. DNA binding motifs for CTCF were downloaded from

423 CTCF_HUMAN.H11MO.0.A on hocomoco11.autosome.org [31]. FIMO (https://meme-

424 <u>suite.org/meme/doc/fimo.html</u> [32]) was used to scan the SMN1/2 gene sequence for CTCF

425 binding motifs. Sequence logos were generated using

- 426 <u>https://weblogo.threeplusone.com/create.cgi</u> [61].
- 427

428 Statistics

429 Required sample size was calculated in R4.4.0 using the pwr v1.3-0 package [62] using the 430 pwr.f2.test function. To detect a medium effect size (Cohen's $f^2=0.15$) [63] in a linear model 431 with a power of 80%, alpha of 0.01 and assuming 4 regression degrees of freedom 432 (corresponding to three covariates), a sample size of 115 is required. Differential methylation 433 analysis was performed using linear models in R4.4.0 with the following formula [64]: 434 dependent variable ~ independent variable + covariates; using methylation percentage as 435 dependent variable. For each independent variable (such as age at sampling or SMA type), 436 one formula was made per CpG site, thus one p-value was calculated for every CpG site 437 and corrected for multiple testing with the false discovery rate (FDR) method. Covariates 438 used were age at sampling in years (except when age was independent variable) [50.65]. 439 sex [66], library size per SMN copy and GQN. Continuous independent variables such as 440 age at sampling were included in the model as numeric values, whereas factors with two 441 levels were converted to 0 and 1. Ordinal independent variables such as SMN2 and NAIP

442 copy number were used as numeric values. SMA type was converted to numeric in the 443 following way before using it as independent variable: type 1 to 0, type 2 to 1, type 3 to 2 and 444 type 4 to 3. For testing concordance in ONT data, the data was divided into two groups due 445 to small sample size: less severe with three copies of SMN2 and type 2b or less severe and 446 with four copies of SMN2 and type 3b or less severe; more severe with three copies of 447 SMN2 and type 2a or more severe and with four copies of SMN2 and type 3a or more 448 severe. Similarly, we compared the less severe group versus the concordant and more 449 severe group taken together. Volcano plots were made by plotting the -log10 of the adjusted 450 p-value against the estimate of the regression coefficient belonging to the independent 451 variable for each CpG site. Results of all statistical tests including effect sizes for all CpG 452 sites are denoted in Table S5. 453

455 **Declarations**

- 456
- 457 Ethics approval and consent to participate
- 458 The study protocol (09307/NL29692.041.09) was approved by the Medical Ethical Committee
- 459 of the University Medical Center Utrecht and registered at the Dutch registry for clinical studies
- 460 and trials (https://www.ccmo.nl/). Written informed consent was obtained from all adult
- 461 patients, and from patients and/or parents additionally in case of children younger than 18462 years old.
- 463
- 464 Consent for publication
- 465 Not applicable.
- 466

467 Declaration of interests

WvR has sponsored research agreements with Biogen and Astra Zeneca. JHV reports to
have sponsored research agreements with Biogen, Eli Lilly and Astra Zeneca. The other
authors declare no competing interests.

471

472 Acknowledgements

We thank the patients who participated in this study. This work was supported by grants from 473 474 Stichting Spieren voor Spieren (to WLvdP), the European Union's Horizon 2020 Research and 475 Innovation Program under the Marie Skłodowska-Curie grant (H2020 Marie Skłodowska-Curie 476 Actions) agreement no. 956185 (SMABEYOND ITN to WLvdP, EJNG) and Prinses Beatrix 477 Spierfonds (W.OB21-01 to EJNG). This project has received funding from the European 478 Research Council (ERC) under the European Union's Horizon 2020 research and innovation 479 programme (grant agreement n° 772376 - EScORIAL). We acknowledge the Utrecht 480 Sequencing Facility (USEQ) for providing sequencing service and data. USEQ is subsidized

481 by the University Medical Center Utrecht and The Netherlands X-omics Initiative (NWO project
482 184.034.019).

- 483
- 484 *Author contributions*

485 Conceptualization, MMZ, MGE, DG, EJNG, GWvH; experimental studies, MMZ, IS, JK, JG,

486 RG; bioinformatics and data analysis MMZ, MGE, DG, HWMvD, JvdS, RAJZ, PJH, WvR;

487 clinical data & patient material, FA, RIW, WLP; writing-original draft, MMZ, EJNG, GWvH;

488 writing–review, all; resources, EJNG, WLvdP; supervision, EJNG, JHV, WLvdP, GWvH;
489 funding acquisition, EJNG, GWvH, WLvdP.

490

491 Data and code availability

492 The datasets used and/or analyzed during the current study are available from the 493 corresponding author on reasonable request but are not publicly available due to privacy 494 restrictions. The code for analyses this available used in study is at: 495 https://github.com/ghaaften/SMA DNA methylation.





- 499 between tissues.
- 500 (A) Overview of sequencing and bioinformatics approaches in this study. Nanopore
- sequencing with adaptive sampling was performed on high molecular weight DNA of SMA 501
- 502 patients. Reads were mapped to SMN1 and phased into haplotypes as described previously

503 [23]. Methylation percentage per CpG site was determined per patient and per haplotype.

504 Created with Biorender.com.

- 505 (B) Heatmap of CpG DNA methylation in and around the SMN2 gene (T2T-CHM13
- 506 chr5:71375000-71425000) in SMA patients with a homozygous SMN1 deletion and one
- 507 patient with one copy of *SMN1* with a pathogenic mutation (indicated with an asterisk). Each
- row represents one patient, each column represents one CpG site. Hierarchical clustering
- 509 with the ward.D2 method was performed on the rows. Patient characteristics are shown left

510 of the heatmap.

- 511 (C) Principal component analysis (PCA) of the methylation data from (B). Blood samples
- 512 (pink) cluster separately from fibroblast samples (orange).
- 513 (D) Differential methylation analysis of DNA methylation between fibroblasts (n=22) and
- 514 blood (n=10). 58 sites are differentially methylated between tissues (p_{adj}<0.01).
- 515 (E) Differential methylation analysis of DNA methylation between more severely (n=6) and
- 516 less severely (n=4) affected patients for blood samples. No differentially methylated sites

517 were found $(p_{adj} < 0.01)$.

- 518 (F) Differential methylation analysis of DNA methylation between more severely (n=10) and
- 519 less severely (n=8) affected patients for fibroblast samples. No differentially methylated sites
 520 were found (p_{adi}<0.01).
- 521 (G) Schematic representation of haplotypes with *SMN1* environment SNVs and *SMN2*522 environment SNVs.
- 523 (H-I) Volcano plot DNA methylation of haplotypes with *SMN1* environment SNVs versus
- 524 haplotypes with SMN2 environment SNVs, for blood (H) and fibroblasts (I). Five differentially
- 525 methylated sites were found in blood and seven sites in fibroblasts. Sample sizes are as

526 indicated in (G).

- 527 (J) Schematic representation of a methylated CpG site, and likely consequences for
- 528 methylation if either the C or G changes to another nucleotide: methylation is not present or
- 529 not detected by the currently used algorithms.
- 530

531 **Table 1:** Baseline characteristics of SMA patients sequenced with Nanopore sequencing

	2xSMN2	3xSMN2	4xSMN2	5xSMN2	Overall
Total	15	215	122	7	359
Sex					
Male	10 (66.7%)	94 (43.7%)	71 (58.2%)	6 (85.7%)	181 (50.4%)
Female	5 (33.3%)	121 (56.3%)	51 (41.8%)	1 (14.3%)	178 (49.6%)
SMA type					
Type 1	15 (100%)	30 (14.0%)	1 (0.8%)	0 (0%)	46 (12.8%)
Type 2	0 (0%)	138 (64.2%)	14 (11.5%)	0 (0%)	152 (42.3%)
Туре 3	0 (0%)	43 (20.0%)	96 (78.7%)	5 (71.4%)	144 (40.1%)
Type 4	0 (0%)	0 (0%)	9 (7.4%)	1 (14.3%)	10 (2.8%)
Presymptomatic	0 (0%)	4 (1.9%)	2 (1.6%)	1 (14.3%)	7 (1.9%)
Age at onset (years)					
Mean (SD)	0.205 (0.153)	1.08 (0.987)	7.39 (9.45)	11.5 (6.23)	3.30 (6.35)
Median [Min, Max]	0.208 [0, 0.500]	0.917 [0, 9.50]	2.50 [0.458, 43.0]	12.5 [1.00, 19.0]	1.08 [0, 43.0]
Missing	1 (6.7%)	11 (5.1%)	13 (10.7%)	1 (14.3%)	26 (7.2%)
Age at sampling (years)					
Mean (SD)	3.57 (4.64)	21.9 (16.9)	35.5 (20.7)	31.2 (14.4)	25.9 (19.6)
Median [Min, Max]	1.86 [0.282, 18.5]	19.6 [0.0438, 64.2]	37.3 [0.189, 79.7]	25.0 [18.0, 52.3]	23.1 [0.0438 79.7]

532 with homozygous SMN1 deletion and no c.859G>C variant in SMN2.

533

medRxiv preprint doi: https://doi.org/10.1101/2024.11.21.24317551; this version posted November 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



535

538 (A) Location of 18 amplicons, 15 of which were sequenced successfully (blue, a total of

539 ~6.6kb around SMN2). Orange indicates amplicons with insufficient coverage for further

- 540 analyses.
- 541 (B) Heatmap of DNA methylation percentage per CpG site determined with targeted bisulfite
- 542 sequencing. Each row represents one patient, each column represents one CpG site.
- 543 Hierarchical clustering with the ward.D2 method was performed on the rows. Patient
- 544 characteristics are shown left of the heatmap. Clustering of patients is mostly based on DNA
- 545 methylation in intron 1 and the 3'UTR.

Figure 2: DNA methylation in the SMN2 gene can be determined by targeted bisulfite
 sequencing.



546

547 Figure 3: DNA methylation in *SMN2* is significantly associated with age at sampling.

548 (A-B) Principal component analysis (PCA) of the methylation data used for statistical

analysis, colored by sex (A) or age (B). Sex clusters overlap completely, whereas age group

550 clusters overlap only partly.

- 551 (C-D) Differential methylation analysis for sex (C) and age at sampling (D) shown with
- volcano plots (n=359). Fifteen sites including collapsed sites, corresponding to 22 CpG sites
- in total, are significantly associated with age (p_{adj} <0.01).

- (E) Methylation percentage of all sites analyzed in the differential methylation analysis.
- 555 Differentially methylated sites from (D) are colored red. DNA methylation significantly
- decreased with age in all tested sites in intron 1 and the 3'UTR, and several sites in the
- promoter and IncRNA and DNA methylation at one site in the promoter significantly
- 558 increased with age. Sites that were collapsed for statistical analysis (see Methods) are
- 559 indicated with an asterisk (*).



F

Dim2 (9.8%)

10

5

0

-5

-10

-10

SMA type

10 15

Dim1 (13.2%)

5.0

2.5

0.0

-5.0 -2.5 0.0 2.5

PCA - dHFMSE

Estimate

10

Dim1 (13.1%)

esponse

Decline

Increase

Stabilization

20

5.0

2.5

0.0

10.0

5.0

2.5

0.0

-1.0

-0.5

Estimate

dHFMSE

0.0 0.5 1.0

Estimate

5.0

G

log₁₀(P_{adj}) 7.5

560

Α

Dim2 (9%)

Е

dHFMSE

10

-10

10

-10

ò

-10



(A-B) Principal component analysis (PCA) of DNA methylation on SMN2 determined by 563

SMN2 CN

3

4

60

bisulfite sequencing, colored by SMN2 copy number (A) or SMA type (B). 564

0

-5

-10

-10

40

Baseline HFMSE score

2

10 15

20

Dim1 (13.3%)

- 565 (C-D) Differential methylation analysis for SMN2 copy number (n=359) (C) and SMA type
- (n=352) (D). No differentially methylated sites were found (p_{adj}<0.01). 566
- (E) Difference in HFMSE score (dHFMSE) 1.5 years after nusinersen treatment versus 567
- 568 before nusinersen treatment in patients with three or four copies of SMN2, plotted against
- 569 baseline HFMSE score.
- 570 (F) PCA of DNA methylation on SMN2 determined by bisulfite sequencing, colored by
- 571 treatment response group based on HFMSE after nusinersen treatment. Treatment response
- was divided as follows: Decrease: dHFMSE≤-3; Stabilization: -3<dHFMSE<3; Increase: 572
- 573 dHFMSE≥3.
- (G) Differential methylation analysis for dHFMSE shown with volcano plots (n=111). No 574
- 575 differentially methylated sites were found (p_{adi}<0.01).
- 576

medRxiv preprint doi: https://doi.org/10.1101/2024.11.21.24317551; this version posted November 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

577 **References**

- 578 1. Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al.
- 579 Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy a
 580 literature review. Orphanet J Rare Dis. 2017;12:124.
- 581 2. Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and
 582 characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80:155–65.
- 583 3. Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, et al. Correlation
 584 between severity and SMN protein level in spinal muscular atrophy. Nat Genet.
 585 1997;16:265–9.
- 4. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene
 regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci.
 1999;96:6307–11.
- 5. Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AHM, et al. A
 Single Nucleotide Difference That Alters Splicing Patterns Distinguishes the SMA Gene
 SMN1 From the Copy Gene SMN2. Hum Mol Genet. 1999;8:1177–83.
- 6. Calucho M, Bernal S, Alías L, March F, Venceslá A, Rodríguez-Álvarez FJ, et al.
 Correlation between SMA type and SMN2 copy number revisited: An analysis of 625
 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord.
 2018;28:208–15.
- 596 7. Wirth B. Spinal Muscular Atrophy: In the Challenge Lies a Solution. Trends Neurosci.597 2021;44:306–22.
- 8. Wadman RI, Jansen MD, Stam M, Wijngaarde CA, Curial CAD, Medic J, et al. Intragenic
 and structural variation in the SMN locus and clinical variability in spinal muscular atrophy.
 Brain Commun. 2020;2:fcaa075.
- 9. Ramos DM, d'Ydewalle C, Gabbeta V, Dakka A, Klein SK, Norris DA, et al. Agedependent SMN expression in disease-relevant tissue and implications for SMA treatment. J
 Clin Invest. 2019;129:4817–31.
- 10. Wadman RI, Stam M, Jansen MD, Weegen Y van der, Wijngaarde CA, Harschnitz O, et
 al. A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with
 Spinal Muscular Atrophy and Healthy Controls. PLOS ONE. 2016;11:e0167087.
- 607 11. Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat
 608 Rev Dis Primer. 2022;8:1–16.
- 609 12. Scheijmans FEV, Cuppen I, van Eijk RPA, Wijngaarde CA, Schoenmakers MAGC, van
 610 der Woude DR, et al. Population-based assessment of nusinersen efficacy in children with
 611 spinal muscular atrophy: a 3-year follow-up study. Brain Commun. 2022;4:fcac269.
- 612 13. Costa-Roger M, Blasco-Pérez L, Cuscó I, Tizzano EF. The Importance of Digging into
 613 the Genetics of SMN Genes in the Therapeutic Scenario of Spinal Muscular Atrophy. Int J
 614 Mol Sci. 2021;22:9029.
- 615 14. d'Ydewalle C, Ramos DM, Pyles NJ, Ng S-Y, Gorz M, Pilato CM, et al. The Antisense
 616 Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for
 617 Spinal Muscular Atrophy. Neuron. 2017;93:66–79.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.21.24317551; this version posted November 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

5. Saffari A, Kölker S, Hoffmann GF, Weiler M, Ziegler A. Novel challenges in spinal
muscular atrophy – How to screen and whom to treat? Ann Clin Transl Neurol. 2019;6:197–
205.

621 16. Chaytow H, Faller KME, Huang Y-T, Gillingwater TH. Spinal muscular atrophy: From
622 approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med.
623 2021;2:100346.

624 17. Greenberg MVC, Bourc'his D. The diverse roles of DNA methylation in mammalian
 625 development and disease. Nat Rev Mol Cell Biol. 2019;20:590–607.

18. Hauke J, Riessland M, Lunke S, Eyüpoglu IY, Blümcke I, El-Osta A, et al. Survival motor
neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease
severity and can be bypassed by histone deacetylase inhibition. Hum Mol Genet.
2009;18:304–17.

630 19. Cao Y, Qu Y, He S, Li Y, Bai J, Jin Y, et al. Association between SMN2 methylation and
631 disease severity in Chinese children with spinal muscular atrophy. J Zhejiang Univ-Sci B.
632 2016;17:76–82.

633 20. Wang J, Bai J, OuYang S, Wang H, Jin Y, Peng X, et al. Antisense oligonucleotides
634 targeting the SMN2 promoter region enhance SMN2 expression in spinal muscular atrophy
635 cell lines and mouse model. Hum Mol Genet. 2022;31:1635–50.

21. Zheleznyakova GY, Voisin S, Kiselev AV, Sällman Almén M, Xavier MJ, Maretina MA, et
al. Genome-wide analysis shows association of epigenetic changes in regulators of Rab and
Rho GTPases with spinal muscular atrophy severity. Eur J Hum Genet. 2013;21:988–93.

639 22. Zheleznyakova GY, Nilsson EK, Kiselev AV, Maretina MA, Tishchenko LI, Fredriksson R,
640 et al. Methylation Levels of SLC23A2 and NCOR2 Genes Correlate with Spinal Muscular
641 Atrophy Severity. PLOS ONE. 2015;10:e0121964.

23. Zwartkruis MM, Elferink MG, Gommers D, Signoria I, Blasco-Pérez L, Costa-Roger M, et
al. Long-read sequencing identifies copy-specific markers of SMN gene conversion in spinal
muscular atrophy [Internet]. medRxiv; 2024 [cited 2024 Oct 2]. p. 2024.07.16.24310417.
Available from: https://www.medrxiv.org/content/10.1101/2024.07.16.24310417v1

- 646 24. Loyfer N, Magenheim J, Peretz A, Cann G, Bredno J, Klochendler A, et al. A DNA
 647 methylation atlas of normal human cell types. Nature. 2023;613:355–64.
- 25. Chen X, Harting J, Farrow E, Thiffault I, Kasperaviciute D, Hoischen A, et al.
- 649 Comprehensive SMN1 and SMN2 profiling for spinal muscular atrophy analysis using long-650 read PacBio HiFi sequencing. Am J Hum Genet. 2023;110:240–50.
- 651 26. Titcombe P, Murray R, Hewitt M, Antoun E, Cooper C, Inskip HM, et al. Human non-CpG
 652 methylation patterns display both tissue-specific and inter-individual differences suggestive
 653 of underlying function. Epigenetics. 2022;17:653–64.
- 654 27. Patil V, Ward RL, Hesson LB. The evidence for functional non-CpG methylation in655 mammalian cells. Epigenetics. 2014;9:823–8.
- 656 28. Shukla S, Kavak E, Gregory M, Imashimizu M, Shutinoski B, Kashlev M, et al. CTCF-
- 657 promoted RNA polymerase II pausing links DNA methylation to splicing. Nature.
- 658 2011;479:74–9.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.21.24317551; this version posted November 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .
- 659 29. Ong C-T, Corces VG. CTCF: an architectural protein bridging genome topology and function. Nat Rev Genet. 2014;15:234-46. 660
- 661 30. Monteagudo-Sánchez A, Noordermeer D, Greenberg MVC. The impact of DNA methylation on CTCF-mediated 3D genome organization. Nat Struct Mol Biol. 2024;31:404-662 663 12.
- 31. Kulakovskiy IV, Vorontsov IE, Yevshin IS, Sharipov RN, Fedorova AD, Rumynskiy EI, et 664 al. HOCOMOCO: towards a complete collection of transcription factor binding models for 665 666 human and mouse via large-scale ChIP-Seq analysis. Nucleic Acids Res. 2018;46:D252-9.
- 667 32. Grant CE, Bailey TL, Noble WS. FIMO: scanning for occurrences of a given motif. 668 Bioinformatics. 2011;27:1017-8.
- 669 33. Marasco LE, Dujardin G, Sousa-Luís R, Liu YH, Stigliano JN, Nomakuchi T, et al. 670 Counteracting chromatin effects of a splicing-correcting antisense oligonucleotide improves 671 its therapeutic efficacy in spinal muscular atrophy. Cell. 2022;185:2057-2070.e15.
- 672 34. Luo R, Bai C, Yang L, Zheng Z, Su G, Gao G, et al. DNA methylation subpatterns at 673 distinct regulatory regions in human early embryos. Open Biol. 2018;8:180131.
- 674 35. McGuire MH, Herbrich SM, Dasari SK, Wu SY, Wang Y, Rupaimoole R, et al. Pan-cancer 675 genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells. 676 EBioMedicine. 2019;43:127–37.
- 677 36. Zhang Q, Sun S, Xie Q, Wang X, Qian J, Yao J, et al. FAM81A Identified as a Stemness-678 Related Gene by Screening DNA Methylation Sites Based on Machine Learning-Accessed 679 Stemness in Pancreatic Cancer. Epigenomics. 2022;14:569-88.
- 680 37. Malumbres M, Pérez de Castro I, Santos J, Fernández Piqueras J, Pellicer A. 681 Hypermethylation of the cell cycle inhibitor p15INK4b 3'-untranslated region interferes with
- 682 its transcriptional regulation in primary lymphomas. Oncogene. 1999;18:385-96.
- 683 38. Maussion G, Yang J, Suderman M, Diallo A, Nagy C, Arnovitz M, et al. Functional DNA 684 methylation in a transcript specific 3'UTR region of TrkB associates with suicide. 685 Epigenetics. 2014;9:1061-70.
- 686 39. Fujii S, Shinjo K, Matsumoto S, Harada T, Nojima S, Sato S, et al. Epigenetic upregulation of ARL4C, due to DNA hypomethylation in the 3'-untranslated region, promotes 687 688 tumorigenesis of lung squamous cell carcinoma. Oncotarget. 2016;7:81571-87.
- 689 40. Shen Z, Zhu L, Zhang C, Cui X, Lu J. Overexpression of BHLHE41, correlated with DNA 690 hypomethylation in 3'UTR region, promotes the growth of human clear cell renal cell 691 carcinoma. Oncol Rep. 2019;41:2137-47.
- 692 41. Koike Y, Sugai A, Hara N, Ito J, Yokoseki A, Ishihara T, et al. Age-related demethylation 693 of the TDP-43 autoregulatory region in the human motor cortex. Commun Biol. 2021;4:1–11.
- 694 42. Wang D, Jia Y, Zheng W, Li C, Cui W. Overexpression of eIF3D in Lung Adenocarcinoma 695 Is a New Independent Prognostic Marker of Poor Survival. Dis Markers. 696 2019;2019:6019637.
- 697 43. Mishra NK, Guda C. Genome-wide DNA methylation analysis reveals molecular 698 subtypes of pancreatic cancer. Oncotarget. 2017;8:28990-9012.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.21.24317551; this version posted November 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- 699 44. Krushkal J, Silvers T, Reinhold WC, Sonkin D, Vural S, Connelly J, et al. Epigenome-700 wide DNA methylation analysis of small cell lung cancer cell lines suggests potential
- 701 chemotherapy targets. Clin Epigenetics. 2020;12:93.
- 702 45. Zou X, Ma W, Solov'yov IA, Chipot C, Schulten K. Recognition of methylated DNA 703 through methyl-CpG binding domain proteins. Nucleic Acids Res. 2012;40:2747-58.
- 704 46. Nanavaty V, Abrash EW, Hong C, Park S, Fink EE, Li Z, et al. DNA Methylation 705 Regulates Alternative Polyadenylation via CTCF and the Cohesin Complex. Mol Cell. 706 2020;78:752-764.e6.
- 707 47. Mitschka S, Mayr C. Context-specific regulation and function of mRNA alternative 708 polyadenylation. Nat Rev Mol Cell Biol. 2022;23:779-96.
- 709 48. Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G. Gene Body Methylation 710 Can Alter Gene Expression and Is a Therapeutic Target in Cancer. Cancer Cell. 711 2014;26:577-90.
- 49. Padeken J, Methot SP, Gasser SM. Establishment of H3K9-methylated heterochromatin 712 713 and its functions in tissue differentiation and maintenance. Nat Rev Mol Cell Biol.
- 714 2022;23:623-40.
- 715 50. Lu AT, Fei Z, Haghani A, Robeck TR, Zoller JA, Li CZ, et al. Universal DNA methylation 716 age across mammalian tissues. Nat Aging. 2023;3:1144-66.
- 717 51. Signoria I, Zwartkruis MM, Geerlofs L, Perenthaler E, Faller KME, James R, et al.
- 718 Patient-specific responses to SMN2 splice-modifying treatments in spinal muscular atrophy 719 fibroblasts. Mol Ther - Methods Clin Dev. 2024;101379.
- 720 52. Morita S, Noguchi H, Horii T, Nakabayashi K, Kimura M, Okamura K, et al. Targeted DNA 721 demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions. 722 Nat Biotechnol. 2016;34:1060-5.
- 723 53. Vojta A, Dobrinić P, Tadić V, Bočkor L, Korać P, Julg B, et al. Repurposing the CRISPR-724 Cas9 system for targeted DNA methylation. Nucleic Acids Res. 2016;44:5615–28.
- 725 54. Wijngaarde CA, Stam M, Otto LAM, van Eijk RPA, Cuppen I, Veldhoen ES, et al.
- 726 Population-based analysis of survival in spinal muscular atrophy. Neurology. 727 2020;94:e1634-44.
- 55. Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. 728
- 729 Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N Engl J Med. 730 2018;378:625-35.
- 731 56. Ewels P, Hüther P, Miller E, Sateesh Peri, Spix N, bot nf-core, et al. nf-core/methylseq: 732 Huggy mollusc [Internet]. Zenodo; 2024 [cited 2024 Nov 17]. Available from:
- 733 https://zenodo.org/records/10463781
- 734 57. R Core Team. R: A Language and Environment for Statistical Computing [Internet].
- 735 Vienna, Austria: R Foundation for Statistical Computing; 2024. Available from: https://www.R-736 project.org/
- 737 58. Kolde R. pheatmap: Pretty Heatmaps [Internet]. 2019 [cited 2024 Nov 19]. Available 738 from: https://cran.r-project.org/web/packages/pheatmap/index.html

- 59. Lê S, Josse J, Husson F. FactoMineR: An R Package for Multivariate Analysis. J Stat
 Softw. 2008;25:1–18.
- 60. Kassambara A, Mundt F. factoextra: Extract and Visualize the Results of Multivariate
- 742 Data Analyses [Internet]. 2020 [cited 2024 Nov 19]. Available from: https://cran.r-
- 743 project.org/web/packages/factoextra/index.html
- 61. Crooks GE, Hon G, Chandonia J-M, Brenner SE. WebLogo: A Sequence LogoGenerator. Genome Res. 2004;14:1188–90.
- 62. Champely S, Ekstrom C, Dalgaard P, Gill J, Weibelzahl S, Anandkumar A, et al. pwr:
- Basic Functions for Power Analysis [Internet]. 2020 [cited 2024 Nov 19]. Available from:
 https://cran.r-project.org/web/packages/pwr/index.html
- 63. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. New York:Routledge; 1988.
- 751 64. Hop PJ, Zwamborn RAJ, Hannon E, Shireby GL, Nabais MF, Walker EM, et al. Genome-
- vide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol
- pathways in ALS. Sci Transl Med. 2022;14:eabj0264.
- 65. Zhang Q, Vallerga CL, Walker RM, Lin T, Henders AK, Montgomery GW, et al. Improved
 precision of epigenetic clock estimates across tissues and its implication for biological
 ageing. Genome Med. 2019;11:54.
- 66. Grant OA, Wang Y, Kumari M, Zabet NR, Schalkwyk L. Characterising sex differences of
 autosomal DNA methylation in whole blood using the Illumina EPIC array. Clin Epigenetics.
 2022;14:62.
- 760